Arm Holdings plc - American Depositary Shares (ARM)
203.36
+21.87 (12.05%)
NASDAQ · Last Trade: Nov 12th, 2:27 AM EST
News & Press Releases
GE Vernova Fell 25% on Data Center Fears. Only About 20% of Its Gas Turbine Customers Are Data Centers. Time to Buy?fool.com
Investors may be viewing this company's future as being more dependent on the AI industry than it actually is.
Via The Motley Fool · November 11, 2026
Chip Stocks Rally After Slide. These Names Are Leading The Charge Higher.investors.com
Chip stocks broadly rallied on Wednesday as investors went bargain-hunting. The Philadelphia semiconductor index, or SOX, surged.
Via Investor's Business Daily · November 11, 2026
Dr. Jaime Haidenberg Leads Plano Plastic Surgery Following the Retirement of Founding Surgeon Dr. Natan Yaker
PLANO, Texas - November 11th, 2026 - Plano Plastic Surgery, at 4100 W 15th Street, Suite 106 in Plano, is led by owner and medical director Dr. Jaime Haidenberg, the medical director and plastic surgeon with 20+ years of experience. Dr. Haidenberg leads the practice following the retirement of founding surgeon Dr. Natan Yaker.
Via AB Newswire · November 11, 2026
SNDL: 3 Key Takeaways for Long-Term Investorsfool.com
A regulatory settlement in Ontario will shrink reported revenue by CAD 105 million while barely denting operating profit, exposing the real earnings power underneath.
Via The Motley Fool · November 11, 2026
2 Stocks I'd Buy Right Now and Hold Through 2035fool.com
Both of these companies are spending heavily today to build the next decade's growth.
Via The Motley Fool · November 11, 2026
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boommarketbeat.com
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
Via MarketBeat · November 11, 2026
Resideo: 3 Key Takeaways for Long-Term Investorsfool.com
Management is betting on branded hardware over third-party OEM work, a shift that could reshape margins for years to come.
Via The Motley Fool · November 11, 2026
Is KKR a Buy After Its Latest Earnings Report?fool.com
The financial company posted an impressive jump in adjusted earnings.
Via The Motley Fool · November 11, 2026
Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studiesmarketbeat.com
Definium Therapeutics (NASDAQ:DFTX) plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said.
The company intends to s
Via MarketBeat · November 11, 2026
After Reading 409 Pickleball Threads, Dearrally Founder Puts Paddle Fit First
Dearrally's founder says the industry is competing on power while buyers are asking whether they can still play next week.
Via Press Release Distribution Service · November 11, 2026
Warning Signs That Your Shoulder Injury Needs Medical Attention
Shoulder injuries can develop from sports, accidents, repetitive movements, or everyday physical activities. While some discomfort may improve with rest and basic care, other symptoms can indicate a more serious condition requiring medical attention. Recognizing these warning signs early can help prevent further damage, improve recovery, and ensure patients receive appropriate treatment.
Via BusinesNews Wire · November 11, 2026
Cellectar (CLRB) Q3 2026 Earnings Call Transcriptfool.com
Management details the phase III trial and U.S. approval timeline for its lead asset.
Via The Motley Fool · November 10, 2026
Cambridge Casual Marks Important Anniversary With the Launch of Hermosa, Its Signature Teak Collection
Launching November 12, Hermosa marks a new design direction in Indonesian teak craftsmanship.
Via Press Release Distribution Service · November 10, 2026
When Independence Is Everything: Simone’s Journey of Finding Accessible, Minimally Invasive Carpal Tunnel Syndrome Relief
(BPT) - For Simone Duven, using her hands isn't optional. Paralyzed from the waist down, she relies on them to move her wheelchair, transfer in and out of bed and shift her weight to help prevent pressure sores. When pain began shooting through both wrists, even everyday movements were tough.
Via Brandpoint · November 10, 2026
Ramp Metals Expands the Rottenstone SW Land Package by 10,562 Ha. Along Strike at Rush
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2026) - Ramp Metals Inc. (TSXV: RAMP) (OTCID: RMPMF) ("Ramp Metals" or the "Company") is pleased to report that it has expanded the Company's Rottenstone SW claim package by an additional 10,562 Ha.
Via Newsfile · November 10, 2026
Optimal Blue report: ARM share hits new high as October lock volume falls 19%
PLANO, Texas, Nov. 10, 2026 (SEND2PRESS NEWSWIRE) -- Optimal Blue today released its October 2026 Market Advantage mortgage data report, which found that adjustable-rate mortgage (ARM) share reached a new high even as rate-lock volume declined across every major loan category. Total rate-lock volume fell 19% month over month (MoM) and 38% year over year (YoY). Purchase volume declined 18% MoM and 17% YoY but still accounted for 84% of October locks, while refinance share fell to 16% of total production.
Via Send2Press · November 10, 2026
As Democrats Take Over Congress, Is Palantir Stock at Risk?fool.com
The AI data analytics stock is now trading 19% below its October high.
Via The Motley Fool · November 10, 2026
What Myomo (MYO) Said on Its Q3 Earnings Callmarketbeat.com
Myomo (NYSEAMERICAN:MYO) reported record third-quarter revenue of $12.3 million, up 22% from a year earlier, and narrowed its full-year revenue guidance as referrals and higher sales of its powered arm braces helped improve operating performance.
The company reached approximately break-even adjuste
Via MarketBeat · November 10, 2026
CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nearsmarketbeat.com
CAMP4 Therapeutics (NASDAQ:CAMP) expects initial data from its SYNGAP1 clinical program in the first half of 2028, as the company prepares to begin dosing patients with a treatment designed to increase expression of a gene associated with a rare neurological disorder.
Chief Executive Officer Josh M
Via MarketBeat · November 9, 2026
Atea Pharma (AVIR) Q3 2026 Earnings Call Transcriptfool.com
Phase 3 hepatitis C data met its endpoints and funding now extends into mid-2028.
Via The Motley Fool · November 9, 2026
Ocular Tx (OCUL) Q3 2026 Earnings Call Transcriptfool.com
Management outlined AXPAXLI's regulatory path and late-stage trial updates.
Via The Motley Fool · November 9, 2026
Is Arm Stock a Buy on the Dip as Agentic AI Opportunity Emerges?fool.com
Arm shares sank despite an upbeat outlook for the company's new CPU business.
Via The Motley Fool · November 9, 2026
Arm and Qualcomm Lead Mobile Chip Design. 1 Stock Is the Better Buy.fool.com
Both of these stocks saw their shares in free fall following earnings.
Via The Motley Fool · November 9, 2026
New Independent Research Hub Launches for Eloralintide, Lilly’s Investigational Amylin Agonist
Eloralintide-Peptide.com brings Phase 2 and Phase 3 trial data, comparisons with semaglutide, tirzepatide, retatrutide and cagrilintide, and sourcing checks together in one place
Via Press Release Distribution Service · November 9, 2026
HTL Recognized as National “Little Giant” Enterprise by MIIT, Expands SMC Manufacturing for Industrial and Robotics Applications
Wuxi, Jiangsu, China, November 9, 2026 -- Wuxi Hengteli Metal Products Co., Ltd. (HTL), a metal component manufacturer based in Wuxi, China, has been recognized as a National-Level Specialized and Sophisticated “Little Giant” Enterprise by China's Ministry of Industry and Information Technology (MIIT). The recognition highlights HTL's position as a specialized manufacturing enterprise, while the company continues to develop its Soft Magnetic Composite (SMC) technology and product portfolio for industrial, energy, and robotics-related applications.
Via Press Release Distribution Service · November 8, 2026